AKTS (Aktis Oncology, Inc. Common stock) Stock Analysis - Insider Trades

Aktis Oncology, Inc. Common stock (AKTS) is a publicly traded the market company. As of May 21, 2026, AKTS trades at $19.03 with a market cap of $1.03B and a P/E ratio of -9.99. AKTS moved +3.03% today. Year to date, AKTS is +24873.80%; over the trailing twelve months it is flat. Its 52-week range spans $0.03 to $29.16. Analyst consensus is strong buy with an average price target of $33.50. Rallies surfaces AKTS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading AKTS stock inside the company?

Recent AKTS insider activity includes Foley Todd bought 232.87K, MPM BIOVENTURES 2018, L.P. bought 1.11M, GADICKE ANSBERT bought 1.11M, EcoR1 Capital, LLC bought 2.08M, and EcoR1 Capital, LLC bought 144.44K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

AKTS Key Metrics

Key financial metrics for AKTS
MetricValue
Price$19.03
Market Cap$1.03B
P/E Ratio-9.99
EPS$-1.89
Dividend Yield0.00%
52-Week High$29.16
52-Week Low$0.03
Volume0
Avg Volume0
Revenue (TTM)$27.38M
Net Income$-167.95M
Gross Margin-2.52%

Recent AKTS Insider Trades

  • Foley Todd bought 232.87K (~$4.19M) on Jan 12, 2026.
  • MPM BIOVENTURES 2018, L.P. bought 1.11M (~$20.03M) on Jan 12, 2026.
  • GADICKE ANSBERT bought 1.11M (~$20.03M) on Jan 12, 2026.
  • EcoR1 Capital, LLC bought 2.08M (~$37.40M) on Jan 12, 2026.
  • EcoR1 Capital, LLC bought 144.44K (~$2.60M) on Jan 12, 2026.

Latest AKTS News

AKTS Analyst Consensus

4 analysts cover AKTS: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $33.50.

Common questions about AKTS

Who is trading AKTS stock inside the company?
Recent AKTS insider activity includes Foley Todd bought 232.87K, MPM BIOVENTURES 2018, L.P. bought 1.11M, GADICKE ANSBERT bought 1.11M, EcoR1 Capital, LLC bought 2.08M, and EcoR1 Capital, LLC bought 144.44K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for AKTS?
Yes. Rallies tracks AKTS insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is AKTS research on Rallies investment advice?
No. Rallies provides research, data, and educational context for AKTS. It does not provide personalized investment advice.
AKTS

AKTS